OUR PORTFOLIO COMPANIES
As early stage investors, Mission Cure Capital expects above-market returns, but our life science portfolio companies are much more than investment opportunities.
As chronic pancreatitis patients, family members and impact investors, we fuel problem-solvers who share our urgency and measure success by improvements in disease progression and quality of life.
Path BioAnalytics
MCC’s investment in Path BioAnalytics (PBA) supported the creation of a new biobank that houses pancreatitis patient cell specimens, matching genetic and clinical data from people who have been diagnosed with pancreatitis or are at high risk of developing pancreatitis.